Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Vernalis plc    VER   GB00B3Y5L754

VERNALIS PLC (VER)
Mes dernières consult.
Most popular
Rapport
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
10/13/2017 10/16/2017 10/17/2017 10/18/2017 10/19/2017 Date
12.125(c) 12.375(c) 12.5(c) 12.75(c) 12.625 Last
72 086 249 623 815 765 79 312 47 895 Volume
-1.02% +2.06% +1.01% +2.00% -0.98% Change
More quotes
Financials ( GBP)
Sales 2018 18,6 M
EBIT 2018 -34,4 M
Net income 2018 -33,3 M
Finance 2018 8,62 M
Yield 2018 -
Sales 2019 30,8 M
EBIT 2019 -28,9 M
Net income 2019 -
Debt 2019 5,00 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 3,15x
EV / Sales2019 2,34x
Capitalization 67,1 M
More Financials
Company
Vernalis Plc is a commercial stage pharmaceutical company.Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic and amoxicillin; and frovatriptan, used for the acute treatment of migraine.Vernalis also develops and... 
More about the company
Surperformance© ratings of Vernalis plc
Trading Rating : Investor Rating :
More Ratings
Latest news on VERNALIS PLC
09/12 VERNALIS : Results Announcement for the year ended 30 June 2017
09/12 VERNALIS PLC : Results Announcement for the year ended 30 June 2017
09/07VERNALIS PLC : annual earnings release
08/08 VERNALIS : FDA Issues a Complete Response Letter on CCP 08 NDA
08/08 VERNALIS PLC : FDA Issues Complete Response Letter on CCP-08 NDA
08/07 VERNALIS : hit by fresh U.S. setback for cough and cold drug
08/07 VERNALIS PLC : FDA Issues Complete Response Letter on CCP-08 NDA
07/18 VERNALIS PLC : Year-End Trading Update and Notice of Full Year Results
04/26 VERNALIS : Gets EUR2 Million Milestone Payments From Servier Partnership
04/24 VERNALIS : FDA Issues a Complete Response Letter on CCP-07 NDA
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
10/08$VER - Vernalis plc #VER Hits New 1-Year Low at $12.25  
09/28$VNLPY - Vernalis plc #VNLPY Rating Increased to Buy at Zacks Investment Rese.. 
09/26Vernalis plc upgraded by Zacks Investment Research to buy. $0.50 PT.  
09/25Vernalis plc $VNLPY Stock Rating Lowered by Zacks Investment Research  
09/23Vernalis plc downgraded by Zacks Investment Research to hold.  
More tweets
Qtime:82
News from SeekingAlpha
09/12 Vernalis reports FY results
08/11 SNIPPET ROUNDUP : A Small Success For Galapagos And A Big One For Karius
04/24 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 23, 2017
04/21 FDA rejects Vernalis' marketing application cough/cold med CCP-07
02/21 Vernalis reports 1H results
Chart VERNALIS PLC
Duration : Period :
Vernalis plc Technical Analysis Chart | VER | GB00B3Y5L754 | 4-Traders
Technical analysis trends VERNALIS PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 0,43  GBP
Spread / Average Target 236%
Managers
NameTitle
Ian Garland Chief Executive Officer & Executive Director
Sandford Sommer President & Chief Operating Officer
Peter John Fellner Non-Executive Chairman
David MacKney Chief Financial Officer & Executive Director
Mike Wood Research Director
Sector and Competitors
1st jan.Capitalization (M$)
VERNALIS PLC-62.50%89
INCYTE CORPORATION14.83%24 254
QUINTILES IMS HOLDINGS INC32.72%21 711
CELLTRION, INC.--.--%20 802
LONZA GROUP59.82%19 730
ALNYLAM PHARMACEUTICALS, INC.213.97%10 783